Nitroglycerin (Sublingual tablet): Difference between revisions

Revision as of 17:28, 31 January 2014

Nitroglycerin
NITROSTAT^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
MINITRAN^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

For patient information, click here.

Revision as of 19:18, 30 January 2014 view source Gerald Chi (talk \| contribs) CMEAdmin, Bureaucrats, bureaucrats, editnews, exportpages, interwiki, nocaptcha, nukepages, smwadministrator, Administrators, Widget editors 17,702 edits mNo edit summary ← Older edit		Revision as of 17:28, 31 January 2014 view source Pratik Bahekar (talk \| contribs) nocaptcha 3,696 edits No edit summary Newer edit →
Line 31:		Line 31:

	==Mechanism of Action==		==Mechanism of Action==
			<ref name="dailymed.nlm.nih.gov">{{Cite web \| last = \| first = \| title = NITROSTAT (NITROGLYCERIN) TABLET [PARKE-DAVIS DIV OF PFIZER INC] \| url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=79ba021e-183c-4b4d-822e-4ff5ef54ca61 \| publisher = \| date = \| accessdate = 31 January 2014 }}</ref>